Solara Active Pharma Sciences Q1 FY27 Earnings Call Transcript Released
Solara Active Pharma Sciences reported Q1 FY27 revenues of ₹384 crore (up 20% YoY) and PAT of ₹16.3 crore (up 55% YoY), with highest EBITDA/PAT in 18 quarters. Base business revenue grew 24% YoY to ₹307 crore. Net debt reduced by ₹135 crore to ₹479 crore. Company targets debt below ₹440 crore by March 2027.
The announcement provides detailed financial results for the quarter, including significant revenue growth, improved profitability, and substantial debt reduction. This information is material for investors and impacts the company's valuation and outlook.
The company reported strong year-on-year growth in revenues, EBITDA, and PAT, reaching multi-quarter highs. Significant debt reduction and clear strategies for future growth and margin improvement contribute to a positive sentiment.
Solara Active Pharma Sciences Limited announced the release of the transcript for their earnings conference call for the quarter ended June 30, 2026. The call was conducted on July 23, 2026, following a Board of Directors meeting.
During the call, MD & CEO Sandeep Rao reported that for Q1 FY27, overall revenues stood at ₹384 crore, a 20% year-on-year increase. EBITDA was ₹63.5 crore, up 10% year-on-year, and PAT was ₹16.3 crore, up 55% year-on-year, marking the highest EBITDA and PAT in the last 18 quarters. The base business revenues were ₹307 crore, up 24% year-on-year, with EBITDA at ₹72 crore, up 8% year-on-year. The commodity Ibuprofen business faced profitability challenges with a negative 12% EBITDA margin.
CFO Sarat Kumar highlighted that despite headwinds from the West Asia crisis impacting input costs and supply chains, the business achieved an EBITDA margin of 17% (₹635 million absolute EBITDA), an 80 basis points Q-on-Q improvement. Net debt was reduced by approximately ₹135 crore during the quarter, with ₹100 crore from the rights issue and ₹35 crore from operational cash flows. The net debt as of June 30, 2026, stands at ₹479 crore, a net debt-to-EBITDA multiple of 1.9x. The company aims to reduce debt to approximately ₹440 crore by March 2027.
Key operational priorities for the next 12-18 months include expanding existing businesses, seeding new ones, driving operational efficiency through debottlenecking, and optimizing working capital. The company is also reviewing its Ibuprofen business, with a resolution expected in H1 FY27. Management expressed confidence in sustaining the growth trajectory of the base business, targeting at least 10% year-on-year growth and maintaining EBITDA margins in the 52% to 55% range.
What to do with a filing like this
Solara Active Pharma Sciences Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Solara Active Pharma Sciences Limited. Read the original for the full detail.